1. Croca SC, Rodrigues T, Isenberg DA. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford). 2011; 50:1424–30.
Article
2. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012; 64:797–808.
Article
3. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012; 71:1771–82.
Article
4. Kidney Disease. Improving global outcomes. (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guidelines for Glomerulonephritis. Kidney Int. 2012; 2 Suppl:139–274.
5. Mok CC, Yap DY, Navarra SV, Liu ZH, Zhao MH, Lu L, et al. Asian Lupus Nephritis Network (ALNN). Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology (Carlton). 2013; [Epub ahead of print].
Article
6. Joo YB, Sung YK, Park YB, Suh CH, Shim SC, Lee YH, et al. Diagnosis and treatment of lupus nephritis: survey results on four important issues. J Rheum Dis. 2013; 20:156–65.
Article
7. Hsieh C, Chang A, Brandt D, Guttikonda R, Utset TO, Clark MR. Predicting outcomes of lupus nephritis with tu-bulointerstitial inflammation and scarring. Arthritis Care Res (Hoboken). 2011; 63:865–74.
Article
8. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford). 2010; 49:128–40.
Article
9. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. The 10-year followup data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010; 69:61–4.
Article
10. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guang-zhou Nephrology Study Group. N Engl J Med. 2000; 343:1156–62.
11. Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Hong Kong Nephrology Study Group. Longterm study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005; 16:1076–84.
Article
12. Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, et al. MAINTAIN Nephritis Trial Group. Azathioprine versus mycophenolate mofetil for longterm immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010; 69:2083–9.
Article
13. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011; 365:1886–95.
Article
14. Yap DY, Ma MK, Mok MM, Tang CS, Chan TM. Longterm data on corticosteroids and mycophenolate mofetil treatment in lupus nephritis. Rheumatology (Oxford). 2013; 52:480–6.
Article
15. Swan JT, Riche DM, Riche KD, Majithia V. Systematic review and meta-analysis of immunosuppressant therapy clinical trials in membranous lupus nephritis. J Investig Med. 2011; 59:246–58.
Article
16. Szeto CC, Kwan BC, Lai FM, Tam LS, Li EK, Chow KM, et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford). 2008; 47:1678–81.
Article
17. Yap DY, Yu X, Chen XM, Lu F, Chen N, Li XW, et al. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology (Carlton). 2012; 17:352–7.
18. Woolf SH. The meaning of translational research and why it matters. JAMA. 2008; 299:211–3.
Article